News for Regulus Therapeutics Stock (RGLS)

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

PRNewsWire • 11/07/24

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 10/08/24

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

PRNewsWire • 08/28/24

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

PRNewsWire • 08/08/24

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

PRNewsWire • 08/06/24

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 06/24/24

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

PRNewsWire • 06/04/24

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

PRNewsWire • 05/16/24

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

PRNewsWire • 05/09/24

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

InvestorPlace • 05/07/24

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 05/06/24

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

PRNewsWire • 04/30/24

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Seeking Alpha • 04/10/24

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

PRNewsWire • 03/21/24

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Zacks Investment Research • 03/13/24

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

PRNewsWire • 03/12/24

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 03/12/24

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 01/02/24

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

PRNewsWire • 11/22/23

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

PRNewsWire • 11/09/23

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 11/02/23

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 10/19/23

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 09/20/23

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PRNewsWire • 09/13/23

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

PRNewsWire • 08/23/23